• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

Artiflex and I-Care phakic IOLs are accurate; some complications exist with both, study finds

Article

Lisbon, Portugal - Both the Artiflex (Ophtec) iris-claw IOL and the I-Care (Cornéal) phakic angle-supported IOL are effective and provide good refractive outcomes, Antonio Marinho, MD, reported Monday at the European Society of Cataract and Refractive Surgeons meeting.

Lisbon, Portugal - Both the Artiflex (Ophtec) iris-claw IOL and the I-Care (Cornéal) phakic angle-supported IOL are effective and provide good refractive outcomes, Antonio Marinho, MD, reported Monday at the European Society of Cataract and Refractive Surgeons meeting.

Over the long term, however, the I-Care IOL was associated with some complications, according to Dr. Marinho. He is from Hospital Arrabida, Porto, Portugal.

In a study, 38 eyes of 25 patients (myopia range, –3.5 to –12 D) were implanted with the Artiflex IOL and 17 eyes of 13 patients (myopia range, –7.5 to –18.5 D) with the I-Care IOL.

No patients implanted with either group lost lines of vision and many eyes gained lines, Dr. Marinho reported.

There were no intraoperative complications with the Artiflex IOL; two of the I-Care IOLs were damaged. Two eyes implanted with the Artiflex IOL developed mild uveitis 2 weeks after implantation that resolved with treatment. Two months after implantation of the I-Care IOL, the IOL rotated in 10 eyes and 18 months after implantation pupil ovalization developed in nine eyes. There were no long-term complications with the Artiflex IOL.

“Both of the IOLs are effective, safe, and stable. Both are implanted with a sutureless surgery. Sizing is still an issue for me with the I-Care IOL; the new model may solve this problem. [With] the Artiflex there were no complications, but I advise prescribing steroids for a few days,” he concluded.

Related Videos
Paul Badawi, co-founder and CEO of Sight Sciences, chats with Neda Shamie, MD, about what drives him
© 2024 MJH Life Sciences

All rights reserved.